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Abstract
Background—The Enterococcus faecium genogroup, referred to as clonal complex 17 (CC17),
seems to possess multiple determinants that increase its ability to survive and cause disease in
nosocomial environments.
Methods—Using 53 clinical and geographically diverse US E. faecium isolates dating from 1971
to 1994 we determined the multi-locus sequence type, the presence of 16 putative virulence genes
(hylEfm, espEfm and fms genes), resistance to ampicillin (AMPR), vancomycin (VANR) and high-
levels of gentamicin and streptomycin.
Results—Overall, 16 different sequence types (STs), mostly CC17 isolates, were identified in 9
different regions of the US. The earliest CC17 isolates were part of an outbreak in 1982 in Richmond,
VA. Characteristics of CC17 isolates included increases in AMPR, the presence of hylEfm and
espEfm, emergence of VANR and the presence of at least 13/14 fms genes. Eight out of forty-one of
the early AMPR isolates, however, were not within CC17.
Conclusions—While not all early US AMPR isolates were clonally related, E. faecium CC17
isolates have been circulating in the US since at least 1982 and appear to have progressively acquired
additional virulence and antibiotic resistance determinants, perhaps explaining the recent success of
this species in the hospital environment.
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INTRODUCTION
Enterococci are commensals of the digestive tract and are now among the leading causes of
nosocomial infections in the United States [1]. Among enterococcal species, Enterococcus
faecalis and Enterococcus faecium are the most frequently encountered [2]. Over the past 2
decades, outbreaks of nosocomial E. faecium infection have become particularly problematic,
increasing to 3.5% of all healthcare-associated infections [3]. The most recent data from the
National Healthcare Safety Network at the Centers for Disease Control and Prevention reported
that E. faecium accounted for approximately one-third of all nosocomial enterococcal related
infections when organisms were identified to the species level[3].
Hospital outbreaks in five continents and the worldwide emergence of multi-resistant E.
faecium have been attributed to a particular genetic lineage designated clonal complex 17
(CC17) [4]. However, a recent publication from Turner et al. [5] suggests that clustering of
multi-locus sequence typing-based allelic profiles using eBURST is unreliable for the ancestral
prediction of species with relatively high recombination rates. Recent efforts by the Willems
and Carrico groups (personal communication) indicate that this is the case for E. faecium by
using novel algorithms such as fBURST (presently being developed by the group of João
Carriço at the Institute for Microbiology, Lisbon University, Portugal), which split CC17 into
smaller clusters. Nevertheless, certain STs (ST16, ST17, ST18, and ST19) appear to be
prominent among the hospital- associated genogroup that has been designated clonal complex
17 (CC17), which we refer to as the CC17 genogroup in this study. CC17 genogroup isolates
are characterized by ampicillin resistance, frequent resistance to vancomycin, and higher rates
than non-CC17 genotypes of virulence determinants such as hylEfm (encoding a hyaluronidase-
like protein) [6] and a putative pathogenicity island which includes espEfm (enterococcal
surface protein in E. faecium) [7,8]. The recently identified fms genes (E. faecium surface
proteins), also enriched in CC17, are factors encoding MSCRAMM (microbial surface
components recognizing adhesive matrix molecules)-like proteins harboring the typical
domains which include a secretion signal sequence, unique regions with Ig-like folds, and a
C-terminal cell-wall anchoring domain with an LPXTG-like motif [9,10]. Such surface
exposed proteins could contribute to virulence by providing a selective advantage in the
hospital setting by conferring, for example, attachment to host tissues and/or environmental
surfaces and possibly by increasing the colonizing ability of strains harboring them [9–11]. In
addition, fms9 (designated ebpCfm in [10]) and fms21 (designated pilA in [12]) have been shown
to encode proteins necessary for pilus formation. The ebpfm encoded proteins are highly similar
to the ebp proteins encoding pili in E. faecalis, which have been previously associated with
pathogenesis in experimental endocarditis [13].
Extensive research has been done on the emergence of ampicillin and vancomycin resistance
and the origins of the CC17 genogroup, mainly in Europe [4,14,15]. Although outbreaks of
ampicillin-resistant E. faecium were first reported in the early 1980’s in the U.S. [16–18],
clonality and population genetics of early U.S. isolates exhibiting ampicillin or vancomycin
resistance have not been characterized. In this study, we determined the clonality of early
ampicillin and vancomycin resistant E. faecium in a US based set of isolates collected between
1971 and 1994. Using these isolates, we analyzed the presence of putative virulence genes in
relation to their clonality and the emergence of ampicillin and vancomycin resistance.
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MATERIALS AND METHODS
Bacterial isolates and species-specific PCR
A total of 53 E. faecium isolates were selected from our collection of over 450 E. faecium
clinical (approximately 75%) and non-clinical isolates (including community, fecal, and
animal isolates) collected between 1970 to the present from diverse origins and geographic
locations with over 15 countries represented. To confirm the identity of the isolates, species
specific amplification of the D-alanyl-D-alanine ligase gene (ddl) was used [19] in addition to
initial biochemical tests. The isolates were selected based on a set of pre-determined criteria
which included: i) the earliest US E. faecium isolates in our collection; ii) isolates recovered
from clinical samples with the majority representing nosocomial outbreaks [16–18,20–22];
and iii) diversity in geographical origin with nine different areas in the US represented (Table
1).
Genomic DNA isolation, multi-locus sequence typing (MLST), and pulsed-field gel
electrophoresis (PFGE)
Genomic DNA was extracted using DNeasy Blood and Tissue Kit (QIAGEN, Inc., Valencia,
Calif.) from 5 ml overnight cultures in brain heart infusion broth (Difco Laboratories, Detroit,
Mich.). PCR and MLST was performed as described previously [23]. Fragments of 7
housekeeping genes (atpA, ddl, gdh, purk, gyd, pstS, and adk) were sequenced, allelic profiles
were obtained, and a ST was designated for each unique allelic profile based on the MLST
website (http://efaecium.mlst.net). For select isolates that had an identical pulsotype to those
of typed strains recovered from the same area or in the same outbreak, only purK was sequenced
and an inferred sequence type was given. Pulsed-field gel electrophoresis was performed as
described previously [26].
Susceptibility testing
Ampicillin and vancomycin susceptibilities and high-level resistance to gentamicin and
streptomycin were determined using standard agar dilution methods [24]. In accordance
Clinical and Laboratory Standards Institute (CLSI) guidelines, minimal inhibitory
concentrations (MICs) of ≥16 µg/ml for ampicillin and ≥ 32 µg/ml for vancomycin were
considered resistant. Isolates with growth on plates with concentrations of 500 µg/ml of
gentamicin and 2000 µg/ml of streptomycin were considered to have high-level resistance.
Colony hybridization and van gene PCR
Preparation of colony lysates on nylon membranes and hybridization under high-stringency
conditions were performed as described previously [25]. DNA probes for hylEfm, espEfm, and
the 14 fms genes were made using primers previously published [6,11] and found in
Supplementary Table 1. Of note, all isolates of this study had the acm gene (fms8) encoding a
collagen-binding adhesin consistent with our previous finding of its presence in the vast
majority of clinical isolates [26]. These probes were radiolabelled using the RadPrime DNA
labeling system (Invitrogen, Carlsbad, Calif.). Vancomycin resistant isolates were tested for
the presence of vanA and vanB genes using the oligodeoxynucleotides and conditions
previously described [19].
Statistical analysis
The difference between CC17 and non-CC17 isolates in their distributions of the fms genes,
hylEfm, espEfm, ampicillin resistance, and vancomycin resistance were compared using two-
tailed Fisher’s exact test. P-values of <0.05 were considered statistically significant.
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RESULTS
While not a prospective collection, the isolates used in this study represent most of the
published E. faecium outbreaks up to 1994 and early reports of ampicillin resistant and
vancomycin resistant strains in the US. In chronological order, the earliest isolates available
to us were from the 1970s and were recovered at the Massachusetts General Hospital in Boston
during a 22-year study at this institution [22]. The 1970’s isolates were both ampicillin and
vancomycin susceptible and MLST analysis revealed that they did not belong to the CC17
genogroup. Instead they were ST296, ST25, or purK allele 8 (NEDH 4901 and NEDH 4586
have an identical pulsotype; data not shown). Colony hybridization analysis showed that these
isolates did not contain the putative virulence determinants hylEfm or espEfm and harbored only
eight to nine of the fourteen fms genes (Supplementary Table 2). High-level resistance to
streptomycin was displayed in two of these isolates.
Two published studies reported ampicillin resistant E. faecium infections between the years of
1981–1987. We obtained seven isolates from one study that occurred at the Rancho Los Amigos
Medical Center in Downey, California between January 1981 and September 1987 [18,27].
This was one of the first reports of an increased presence of ampicillin resistance (MICs 16–
32 µg/ml). We found high-level resistance to streptomycin in some of the isolates but none
had high-level resistance to gentamicin and all were vancomycin susceptible. Six of the isolates
were ST92, ST476 or contained purK allele 2 (RLA-5 and RLA-7 had an identical pulsotype
while RLA-1, 2, and 3 had an identical pulsotype; data not shown and [27]), which indicated
that they were not related to the CC17 genogroup. The hylEfm and espEfm genes were not present
and the fms gene profile showed these isolates were missing the predicted pilus operon
fms11-19-16, putative accessory pilin fms20, and putative adhesin fms18. One isolate was
ST280 (within the CC17 genogroup) and contained all 14 of the fms genes; the exact year
(between 1981–87) this organism was isolated is unknown.
We also found that CC17 genogroup isolates from the second study during this time frame
were responsible for an E. faecium outbreak in a neonatal intensive care unit in 1982 at the
Medical College of Virginia in Richmond [17,27]. This outbreak was the first report describing
bacteremia and meningitis due to multi-resistant E. faecium. Seven isolates were studied from
this outbreak and we found that all belonged to ST17 by MLST or harbored the purK allele 1
(MCV161 and 130 had an identical pulsotype while MCV264, 211, and 255 had an identical
pulsotype; data not shown and [27]). This outbreak was different from the California outbreak
in that ampicillin MICs were slightly higher, ranging from 32 to 64 µg/ml and this is the first
time that E. faecium with high-level resistance to gentamicin was observed in our study, and
to our knowledge, in the US. These early isolates contained all of the fms genes; only one isolate
from this outbreak had the espEfm gene and none had the hylEfm gene.
We examined ten isolates recovered in four different states between the years 1986 and 1988.
Two isolates were from two different hospitals in Boston, Massachuchetts [20,22], one from
a nosocomial outbreak of E. faecium at Miriam Hospital in Providence, Rhode Island [28],
three from Charlotte Memorial Hospital in North Carolina [29], and four from the University
of Wisconsin at Madison clinics [30]. One isolate from the Children’s Hospital Medical Center
in Boston, MA had been obtained because of its reported high-level resistance to gentamicin
[20]. This isolate was found to be ST112 and therefore did not belong to CC17; it was isolated
in 1986, had an intermediate ampicillin MIC of 8 µg/ml and lacked the ebpfm operon fms1–5–
9 but had the espEfm gene. Another Boston isolate, recovered in 1988 at New England
Deaconess Hospital, had a new ST, ST473, with purK allele 8, was ampicillin resistant (MIC
32 µg/ml) and lacked the putative adhesins scm (fms 10), fms15 and fms18. Four of the ten
isolates in this time period were within the CC17 genogroup, specifically ST18, ST19, or
purK allele 1 (M-1634 and W-27358 had an identical pulsotype; data not shown). The others
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were ST10, ST25 or a new ST, ST474. Four isolates from locations other than Boston were
ampicillin resistant (three within the CC17 genogroup and one not) with MICs between 16 and
64 µg/ml. The majority of the ten isolates showed high-level resistance to streptomycin (seven
out of ten), but only one to gentamicin. All four CC17 genogroup isolates contained all fms
genes, three contained the espEfm gene and two contained hylEfm. The two isolates that
contained the hylEfm gene were isolated in 1986; this is the first appearance of the hylEfm gene
in this study.
In addition to the ten isolates described above, six isolates from the Medical College of
Pennsylvania in Philadelphia isolated in the 1988 were also studied [16]. These isolates were
from a surveillance study showing an increase in penicillin resistance and an inability to treat
some of these isolates with combination gentamicin/penicillin therapy. We found that all six
isolates were within the CC17 genogroup with ST16, ST17, or purK allele 1 (FA295 and FA287
had an identical pulsotype while FA232 and FA191 had a similar pulsotype; data not shown
and [27]) and had all 14 fms genes. They were all ampicillin resistant and vancomycin
susceptible with ampicillin MICs ranging between 32 and 128 µg/ml. High-level resistance to
streptomycin was present in five of the isolates while high-level resistance to gentamicin was
found in three of the isolates during this time period. Five of the isolates contained the
espEfm gene but none contained the hylEfm gene.
We also had available isolates from two published outbreaks occurring during the years 1990–
1991 [21,22]: four isolates were obtained from Boston (two from New England Deaconess
Hospital and two from the 22-year review study at Massachusetts General Hospital) [22] and
eight isolates were obtained from a multi-resistant E. faecium nosocomial outbreak at Beth
Israel Hospital in New York [21]. This was the first time we documented vancomycin resistant
isolates in this study. Isolates from both outbreaks were all representatives of the CC17
genogroup, specifically ST18, ST16, ST17, or with the purK allele 1 (SH-4, 5 and 10 had
identical pulsotypes while SH-6, 9, 11, 13 and 14 had similar pulsotypes; data not shown and
[21]). The majority of isolates were ampicillin resistant with even higher MICs than the
outbreaks in the late 1980’s, ranging from 32–256 µg/ml. The isolates from Boston were
vancomycin susceptible while the isolates from New York exhibited vancomycin resistance
conferred by the vanA gene with MICs between 256–512 µg/ml. Both outbreaks had isolates
with high-level resistance to both gentamicin and streptomycin. Interestingly, all isolates in
both outbreaks contained hylEfm and espEfm, highlighting a marked increase in the presence of
these two genes. Furthermore, most contained all 14 fms genes except that none of the New
York isolates had the putative accessory pilus encoding gene, fms20.
Lastly, we also studied eight isolates recovered in Houston, Texas at two different hospitals
between 1992 and 1994 [31]. Five isolates were within the hospital-associated CC17
genogroup with ST20, ST17, and purK allele 1 represented (VREH-1 and 4 had similar pulsed-
field types; data not shown). These isolates exhibited ampicillin resistance with MICs between
32–128 µg/ml and two exhibited vanA-type of vancomycin resistance (MIC 512µg/ml). The
majority of isolates exhibited high-level resistance to streptomycin (5 out of 8), but only one
to gentamicin. The Texas CC17 genogroup isolates had the majority of fms genes, except for
fms20 and fms18. The hylefm and espefm genes were detected in only one of these isolates. We
also identified a new CC17 genogroup related ST, ST475, in this group of isolates represented
by isolate TX1399, a single locus variant of ST17 in the ddl allele. This isolate was susceptible
to both ampicillin and vancomycin but had the same fms, hylEfm and espEfm gene profile as the
other Texas CC17 isolates. Two of the strains isolated were not within the CC17 genogroup
(ST71 and purK allele 8). Both were ampicillin and vancomycin susceptible and one showed
high-level resistance to streptomycin; these two isolates lacked the hylEfm and espEfm genes
and contained only seven or eight of the fourteen fms genes.
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DISCUSSION
In this study, MLST was performed on clinical isolates to determine the clonality of early US
ampicillin resistant isolates and the earliest hospital-associated CC17 genogroup isolate in our
collection. For the isolates in this study, eight out of the forty-one ampicillin resistant isolates
were not CC17 genogroup related isolates, showing that not all ampicillin resistant isolates
were clonally related. However, the presence of ampicillin resistance in CC17 isolates versus
non-CC17 isolates was statistically significant (P = 0.0007). While the earliest CC17
genogroup isolate may have been recovered in 1981 in California, ST17 isolates were clearly
present in U.S. hospitals by 1982. This predates the earliest published CC17 genogroup isolate,
which was recovered in Great Britain, by more than seven years and predates the previously
earliest known US CC17 genogroup isolate (DO/ TX0016) by nine years
(http://efaecium.mlst.net). The earliest CC17 genogroup isolates recovered in this study were
ampicillin resistant and most exhibited high-level resistance to streptomycin as well.
Interestingly, all of the earliest CC17 genogroup isolates contained all fourteen fms genes but
the majority lacked espEfm and hylEfm genes.
Although E. faecium has been shown to be relatively intrinsically resistant to β-lactam
antibiotics [32] leading to sporadic reports of such isolates as early as 1965 [15], reports of
infections caused by highly ampicillin resistant E. faecium did not occur until the 1980’s
[16–18,28,33]. The fact that ampicillin resistance existed in the earliest CC17 genogroup
isolates is consistent with the hypothesis that ampicillin resistance may have been one of the
first steps of hospital-adaptation by the hospital-associated CC17 genogroup [4]. Only two of
the CC17 genogroup isolates in this study were ampicillin susceptible. Within the CC17
genogroup isolates, ampicillin MICs progressively increased over time, a finding that is
consistent with the fact that events such as further mutations or overexpression of the pbp5
gene might have evolved in these isolates, further decreasing the affinity for ampicillin.
Evidence suggests that particular substitutions present in combination amplify levels of
resistance [34,35]. Additionally, there is some evidence that indicates that emergence of high-
level ampicillin resistance among US E. faecium strains is due, at least in part, to the transfer
of low-affinity pbp5 between clinical isolates, a situation that we cannot rule out in this study
[36]. Our data confirm that ampicillin resistance preceded the emergence of vancomycin
resistance within the CC17 genogroup in the United States, as has been shown in European
studies [15,37]. The earliest known vancomycin resistant E. faecium strain was isolated in
Europe in 1986 [38,39]. Among our isolates, vancomycin resistance (P = 0.044 for CC17 versus
non-CC17) first appeared among CC17 genogroup isolates in 1990 by acquiring the vanA gene
cluster. Curiously, vancomycin resistance conferred by vanB in US E. faecium was not reported
until around 1992 but numerous cases/outbreaks of E. faecium expressing the vanB type were
described in the US thereafter; at least some of which are known to be CC17 [40–43].
We also found that all the isolates within the CC17 genogroup contained a similar fms gene
profile with all isolates containing at least thirteen of the fourteen fms genes (with either
fms20 or fms18 missing), a result that is clearly different from non-CC17 isolates where only
five to nine fms genes were identified (P-values ranging from 0.001 to 0.029 for all fms genes
except fms20) (Figure 3 and Supplementary Table 2). These data correspond with reports from
Hendrickx et al. and Sillanpaa et al. demonstrating the enrichment of putative cell-wall
anchored protein genes in clinical and outbreak-associated E. faecium isolates [9,11]. Indeed,
the earliest CC17 genogroup isolates in the study contained all 14 fms genes.
Previous studies have indicated that espEfm is an important genetic marker for the previously
designated E. faecium CC17 [8,44]. Our findings show that espEfm, whose presence in CC17
isolates versus non-CC17 isolates was statistically significant (P = 0.0002), was present in one
of the earliest ST17 isolates (TX2038 isolated in 1982), however, it was not present in most
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of the early published outbreak isolates. This finding suggests that espEfm, present in a putative
pathogenicity island, was likely acquired at different times during this genogroup’s evolution
and that the fms genes are more likely to be early markers of the CC17 genogroup in the USA.
Interestingly, it has recently been shown that hylEfm is on a transferable plasmid which increases
both the virulence and colonizing abilities of CC17 genogroup clinical isolates [45], (C.A.A.
and B.E.M., unpublished data). This plasmid also appears to carry antibiotic resistance genes
in certain CC17 genogroup clinical isolates, such as gentamicin and vancomycin resistance
encoded by the aac(6’)-aph(2”) and vanA genes (C.A.A. and B.E.M., unpublished data).
Indeed, in this study, almost all of the vancomycin-resistant strains also exhibited high-level
resistance to gentamicin and contained the hylEfm gene. Our findings indicate that the presence
of hylEfm (P = 0.001 for CC17 versus non-CC17) increased around the late 1980’s in the
evolution of the CC17 genogroup. Therefore, it is tempting to speculate that ancestral hospital-
associated genogroup isolates in the USA carrying the fms genes, subsequently acquired
espEfm and/or the transferable hylEfm-containing plasmid (which may or may not contain
vancomycin and gentamicin resistance determinants) and these series of events may help
explain the recent success of this organism as a nosocomial pathogen.
In summary, we demonstrated that hospital-associated isolates within the CC17 genogroup
have been circulating in the United States as early as 1982. Our data indicate that even though
most of the earliest ampicillin resistant isolates were part of the CC17 genogroup, ampicillin
resistance seemed to be acquired independently of CC17. This is indicated by the fact that not
all CC17 isolates are ampicillin resistant (two isolates), and not all ampicillin resistant isolates
were within the CC17 genogroup (eight isolates). Furthermore, all vancomycin resistant
isolates in this study were a part of the CC17 genogroup. Our data suggest that fms genes
(putative pili or adhesins) were more associated with early CC17 genogroup-related STs than
other putative virulence genes and, thus, the fms gene profile may be a more accurate marker
of a CC17 genogroup isolate than the presence of ampicillin resistance, espEfm, or hylEfm. These
data support the concept that hospital-adapted clones may not have evolved recently from a
single founder, but that different hospital-adapted clones (STs) have evolved independently
and become successful by acquiring antibiotic resistances and potential virulence factors such
as the fms genes, espEfm, and hylEfm.
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Figure 1.
Key events that occurred in the isolates of this study. The MICs listed correspond to the highest
ampicillin MIC from each outbreak. The following abbreviations are used in this figure: high-
level resistance to streptomycin (STRHLR), high-level resistance to gentamicin (GENHLR),
ampicillin resistance (AMPR) and vancomycin resistance (VANR)
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Figure 2.
A comparison between CC17 isolates and non-CC17 isolates for the presence of ampicillin
resistance, vancomycin resistance, the espEfm gene, and the hylEfm gene. * P < 0.05 against
non-CC17 isolates in our study. ** P < 0.005 against non-CC17 isolates in our study. *** P <
0.0005 against non-CC17 isolates in our study
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Figure 3.
A comparison between CC17 and non-CC17 isolates for the presence of the putative adhesins
and pili (fms) genes. fms1-5-9 is the ebpfm operon while fms11-19-16 and fms 14–17–13 are
putative pilus operons. fms21 has been shown to encode pili while fms20 is considered its
accessory protein. fms10, also known as scm, is a collagen binding adhesin while fms18 and
fms15 are thought to encode putative adhesins. * P < 0.05 against non-CC17 isolates in our
study. ** P < 0.005 against non-CC17 isolates in our study. *** P < 0.0005 against non-CC17
isolates in our study
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